ALLO just delivered its Q1 2026 results, and the headline number came in better than feared. EPS landed at -$0.18, a penny ahead of the -$0.19 consensus. The stock is up about 6% on the week at $2.30. Yet short sellers have been moving in the opposite direction — adding exposure at a pace not seen in months. That divergence between a modest beat and accelerating short interest is the tension worth unpacking this week.
Short interest has doubled over six weeks. At 16.4% of free float — up from roughly 9% in late March — the position is substantial and growing fast. The week-on-week increase of 8.3% was the sharpest of the past month. Looking at the history, the inflection came in mid-April around the 10th, when shares short jumped from ~24.9M to ~32.3M in a single session. They have not looked back. What is notable is that this has happened while the cost to borrow remains almost irrelevant — currently 0.48% annualised. Availability is wide open. With borrowing this cheap and supply this plentiful, there is no mechanical brake on further short-building if sentiment deteriorates.
Options positioning, by contrast, tells a calmer story. The put/call ratio is running near its 20-day average at 0.32, a fraction of a standard deviation above the mean. The 52-week range spans 0.07 to 1.27, which makes the current reading firmly neutral — neither hedging into downside nor leaning bullish. Options traders appear content to sit on the sidelines while short sellers do the heavier directional lifting.
The Street has been broadly constructive, but with important caveats. A cluster of firms raised targets around mid-April — Jefferies lifted to $10, HC Wainwright to $12, Baird to $9, and Citizens to $8 — largely in response to interim clinical data from the Phase 3 Alpha3 trial of cema-cel. JP Morgan upgraded to Neutral around the same time, removing an Underweight that had weighed on sentiment. However, all of these moves are now approaching four weeks old, which is an eternity relative to where the stock is trading. At $2.30, the gap between the current price and the mean analyst target of roughly $8.50 is wide. The bull case centres on cema-cel's potential to bring CAR-T therapy into the community setting; the bear case flags a 60% success probability for the flagship programme, slow revenue ramp, and no near-term path to profitability — the EV/EBITDA multiple is a deeply negative -1.74, and the P/E similarly reflects a loss-making business. The analyst rec diff factor score ranks in the 92nd percentile, suggesting consensus is relatively bullish relative to the universe — but that consensus was formed before the latest short-building wave.
On the ownership side, a notable item landed today alongside earnings: Allogene terminated its exclusive licence agreement with Overland Therapeutics, effective May 12. No termination payments were made, and Allogene retains roughly 3% of Overland equity after surrendering a portion for no consideration. It is not obvious that this is materially value-destructive, but it removes a potential partnering narrative. Separately, Frazier Life Sciences added a significant 16.2M share position as of April 16, and T. Rowe Price added 1.7M shares through March — institutional buyers are present. However, insider flows have been one-directional: CEO David Chang and CTO Ben Beneski have both been selling in small regular clips since February, with Chang alone disposing of over $289,000 worth at prices between $1.73 and $2.47.
Allogene's history on earnings days has been unforgiving. The March 12 print saw the stock fall 8.7% on the day and 15.6% over the subsequent five days. The May 7 pre-earnings event produced a -1.3% move. The next event is scheduled for June 18 — the catalyst calendar is not far away. With short interest at a six-week high, a clean Q1 beat already in the tape, and the Overland licence exit absorbing attention, the June print and any interim cema-cel data updates become the next material tests for positioning on both sides.
See the live data behind this article on ORTEX.
Open ALLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
